Last reviewed 2026-04-20 · How we verify

Glulisine Insulin

Glulisine Insulin, marketed by Emory University, is a rapid-acting insulin analog currently available in the diabetes market. The key composition patent for Glulisine Insulin is set to expire in 2028, which may provide a period of exclusivity and market protection. The primary risk is the potential increase in competition following the patent expiry, which could impact market share and revenue.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal. (PHASE4)
• Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus Patients (PHASE3)
• Afrezza® INHALE-1 Study in Pediatrics (PHASE3)
• Degludec Glargine U300 Hospital Study (NA)
• Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) (PHASE4)
• Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN) (NA)
• Closed Loop From Onset in Type 1 Diabetes (NA)
• Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.